Skip to content
OpenCapital
Get started

NuSkin Enterprises NUS Payments to Noncontrolling Interests

Payments to Noncontrolling Interests at other companies

USANA Health Sciences logo
USANA Health SciencesUSNA
$1.38M—

Other financials

Income statement

See full
Revenue$320.6M-12.0%
Gross profit$214.5M-13.2%
Operating income$4.0M+141%
Net income$1.8M-98.3%
EPS (diluted)$0.04-98.1%

Balance sheet

See full
Cash & equivalents$198.7M-2.5%
Total debt$303.6M-8.2%
Total equity$794.1M+5.3%
Total assets$1.4B-1.1%

Cash flow

See full
Operating cash flow-$3.9M-1,107%
CapEx$13.7M+1.0%
Free cash flow-$17.6M-33.6%

Valuation

See full
Market cap$256.35M-38.2%

Where this comes from

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToMinorityShareholders.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about NuSkin Enterprises's payments to noncontrolling interests.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NuSkin Enterprises's payments to noncontrolling interests?
NuSkin Enterprises (NUS) reported payments to noncontrolling interests of $6.5M in Q1 2026.